Z
Zheng Huang
Researcher at Merck & Co.
Publications - 50
Citations - 2509
Zheng Huang is an academic researcher from Merck & Co.. The author has contributed to research in topics: Stearoyl-CoA Desaturase & Phospholipase A2. The author has an hindex of 26, co-authored 50 publications receiving 2419 citations. Previous affiliations of Zheng Huang include United States Military Academy.
Papers
More filters
Journal ArticleDOI
Rapid measurement of deuterium-labeled long-chain fatty acids in plasma by HPLC-ESI-MS.
Sébastien Gagné,Sheldon Crane,Zheng Huang,Chun Sing Li,Kevin P. Bateman,Jean-François Lévesque +5 more
TL;DR: A new and rapid method for the quantification of deuterium-labeled fatty acids in plasma by HPLC-MS is reported, which improved the limit of detection (LOD) significantly, depending on the products analyzed.
Journal ArticleDOI
Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series
Nicolas Lachance,Yves Gareau,Sébastien Guiral,Zheng Huang,Elise Isabel,Jean-Philippe Leclerc,Serge Leger,Evelyn Martins,Christian Nadeau,Renata Oballa,Stéphane G. Ouellet,David A. Powell,Yeeman K. Ramtohul,Geoffrey K. Tranmer,Thao Trinh,Hao Wang,Lei Zhang +16 more
TL;DR: This work has found novel, potent and structurally diverse liver-targeted bispyrrolidine SCD inhibitors that possess suitable cellular activity and pharmacokinetic properties to inhibit liver SCD activity in a mouse pharmacodynamic model.
Journal ArticleDOI
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
Dwight Macdonald,Anthony Mastracchio,Helene Perrier,Daniel Dube,Michel Gallant,Patrick Lacombe,Denis Deschenes,Bruno Roy,John Scheigetz,Kevin P. Bateman,Chun Li,Laird A. Trimble,Stephen Day,Nathalie Chauret,Deborah A. Nicoll-Griffith,José M. Silva,Zheng Huang,Susana Liu,Diane Ethier,Doug Pon,Eric S. Muise,Louise Boulet,Chi-Chung Chan,Angela Styhler,Stella Charleson,Joseph A. Mancini,P. Masson,David Claveau,Donald W. Nicholson,Mervyn J. Turner,Robert N. Young,Yves Girard +31 more
TL;DR: The discovery and SAR of a new series of substituted 8-arylquinoline PDE4 inhibitors led to the identification of several compounds with excellent in vitro and in vivo profiles, including a good therapeutic window of emesis to efficacy in several animal models.
Journal ArticleDOI
Biological activity and preclinical efficacy of azetidinyl pyridazines as potent systemically-distributed stearoyl-CoA desaturase inhibitors
Elise Isabel,David A. Powell,W. Cameron Black,Chi-Chung Chan,Sheldon Crane,R. Gordon,Jocelyne Guay,Sébastien Guiral,Zheng Huang,Joel Robichaud,Kathryn Skorey,Paul Tawa,Lijing Xu,Lei Zhang,Renata Oballa +14 more
TL;DR: In a one-month gDIO mouse model of obesity, it was demonstrated that there was no therapeutic index even at low doses; efficacy in preventing weight gain tracked closely with skin and eye adverse events.
Journal ArticleDOI
L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
Zheng Huang,Rebecca Dias,Thomas R. Jones,Suzanna Liu,Angela Styhler,David Claveau,F. Otu,K. Ng,F. Laliberte,L. Zhang,Pascal Jean Denis Goetghebeur,William M. Abraham,Dwight Macdonald,Daniel Dube,Michel Gallant,Patrick Lacombe,Yves Girard,Robert N. Young,Mervyn J. Turner,Donald W. Nicholson,Joseph A. Mancini +20 more
TL;DR: The preclinical profile of L-454,560 is delineated, which is a novel PDE4 inhibitor with an overall in vivo efficacy profile at least comparable to roflumilast and clearly superior to cilomilast.